{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:41:01Z","timestamp":1781124061254,"version":"3.54.1"},"reference-count":70,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH NIAID","award":["5R21AI163915-02"],"award-info":[{"award-number":["5R21AI163915-02"]}]},{"name":"Vaxcyte Inc.","award":["5R21AI163915-02"],"award-info":[{"award-number":["5R21AI163915-02"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Chlamydia trachomatis (Ct) is the most common cause of bacterial sexually transmitted infections (STIs) worldwide. Ct infections are often asymptomatic in women, leading to severe reproductive tract sequelae. Development of a vaccine against Chlamydia is crucial. The Chlamydia major outer membrane protein (MOMP) is a prime vaccine antigen candidate, and it can elicit both neutralizing antibodies and protective CD4+ T cell responses. We have previously designed chimeric antigens composed of immunogenic variable regions (VDs) and conserved regions (CDs) of MOMP from Chlamydia muridarum (Cm) expressed into a carrier protein (PorB), and we have shown that these were protective in a mouse model of Cm respiratory infection. Here, we generated corresponding constructs based on MOMP from Ct serovar F. Preliminary structure analysis of the three antigens, PorB\/VD1-3, PorB\/VD1-4 and PorB\/VD1-2-4, showed that they retained structure features consistent with those of PorB. The antigens induced robust humoral and cellular responses in mice with different genetic backgrounds. The antibodies were cross-reactive against Ct, but only anti-PorB\/VD1-4 and anti-PorB\/VD1-2-4 IgG antibodies were neutralizing, likely due to the antigen specificity. The cellular responses included proliferation in vitro and production of IFN-\u03b3 by splenocytes following Ct re-stimulation. Our results support further investigation of the PorB\/VD antigens as potential protective candidates for a Chlamydia subunit vaccine.<\/jats:p>","DOI":"10.3390\/vaccines12070789","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T08:39:12Z","timestamp":1721291952000},"page":"789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Structural Assessment of Chlamydia trachomatis Major Outer Membrane Protein (MOMP)-Derived Vaccine Antigens and Immunological Profiling in Mice with Different Genetic Backgrounds"],"prefix":"10.3390","volume":"12","author":[{"given":"Shea K.","family":"Roe","sequence":"first","affiliation":[{"name":"Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianmou","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoli","family":"Slepenkin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aym","family":"Berges","sequence":"additional","affiliation":[{"name":"Vaxcyte Inc., 825 Industrial Road, Suite 300, San Carlos, CA 94070, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Fairman","sequence":"additional","affiliation":[{"name":"Vaxcyte Inc., 825 Industrial Road, Suite 300, San Carlos, CA 94070, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"de la Maza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-0711","authenticated-orcid":false,"given":"Paola","family":"Massari","sequence":"additional","affiliation":[{"name":"Department of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"ref_1","unstructured":"CDC (2019). Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Newman, L., Rowley, J., Vander Hoorn, S., Wijesooriya, N.S., Unemo, M., Low, N., Stevens, G., Gottlieb, S., Kiarie, J., and Temmerman, M. (2015). Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143304"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1128\/iai.59.11.4147-4153.1991","article-title":"Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies","volume":"59","author":"Peterson","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM197802232980805","article-title":"Chlamydial infections (first of three parts)","volume":"298","author":"Schachter","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1086\/513844","article-title":"Chlamydia trachomatis infections: Progress and problems","volume":"179","author":"Stamm","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/infdis\/jiab031","article-title":"Pelvic Inflammatory Disease Due to Neisseria gonorrhoeae and Chlamydia trachomatis: Immune Evasion Mechanisms and Pathogenic Disease Pathways","volume":"224","author":"Darville","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00365540110077001","article-title":"Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?","volume":"34","author":"Gotz","year":"2002","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1086\/497341","article-title":"The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection","volume":"192","author":"Brunham","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1067\/mob.2002.121625","article-title":"Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial","volume":"186","author":"Ness","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1016\/j.vaccine.2017.10.075","article-title":"National Institute of Allergy and Infectious Diseases workshop report: \u201cChlamydia vaccines: The way forward\u201d","volume":"37","author":"Zhong","year":"2019","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rodrigues, R., Marques, L., Vieira-Baptista, P., Sousa, C., and Vale, N. (2022). Therapeutic Options for Chlamydia trachomatis Infection: Present and Future. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111634"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0002-9394(67)94095-0","article-title":"Pannus with experimental trachoma and inclusion conjunctivitis agent infection of Taiwan monkeys","volume":"63","author":"Wang","year":"1967","journal-title":"Am. J. Ophthalmol."},{"key":"ref_13","unstructured":"Taylor, H.R. (2008). Trachoma: A Blinding Scourge from the Bronze Age to the Twenty-First Century, Centre for Eye Research Australia."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/21505594.2015.1111509","article-title":"Chlamydial polymorphic membrane proteins: Regulation, function and potential vaccine candidates","volume":"7","author":"Vasilevsky","year":"2016","journal-title":"Virulence"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.vaccine.2011.01.074","article-title":"Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge","volume":"29","author":"Murthy","year":"2011","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1128\/IAI.73.12.8153-8160.2005","article-title":"Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria","volume":"73","author":"Pal","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/IAI.00881-10","article-title":"Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model","volume":"79","author":"Farris","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.4049\/jimmunol.0804375","article-title":"Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: Implication for a trachoma transmission-blocking vaccine","volume":"182","author":"Kari","year":"2009","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15087","DOI":"10.1038\/s41598-023-42296-7","article-title":"Efficacy of a synthetic peptide Chlamydia pecorum major outer membrane protein vaccine in a wild koala (Phascolarctos cinereus) population","volume":"13","author":"Simpson","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0264-410X(98)00219-9","article-title":"Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge","volume":"17","author":"Pal","year":"1999","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"33241","DOI":"10.18632\/oncotarget.16601","article-title":"DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1110\/ps.3650102","article-title":"Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia","volume":"11","author":"Bush","year":"2002","journal-title":"Protein Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1128\/JB.00552-07","article-title":"Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis","volume":"189","author":"Sun","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Feher, V.A., Randall, A., Baldi, P., Bush, R.M., de la Maza, L.M., and Amaro, R.E. (2013). A 3-dimensional trimeric beta-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068934"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1084\/jem.167.3.817","article-title":"High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis","volume":"167","author":"Stephens","year":"1988","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/IAI.68.3.1719-1723.2000","article-title":"T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans","volume":"68","author":"Ortiz","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nunes, A., Nogueira, P.J., Borrego, M.J., and Gomes, J.P. (2010). Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: Worldwide survey. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013171"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Olsen, A.W., Lorenzen, E.K., Rosenkrands, I., Follmann, F., and Andersen, P. (2017). Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01652"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/IAI.00749-16","article-title":"IFNgamma is Required for Optimal Antibody-Mediated Immunity against Genital Chlamydia Infection","volume":"84","author":"Naglak","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.4049\/jimmunol.1103032","article-title":"CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract","volume":"189","author":"Gondek","year":"2012","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.vaccine.2005.08.074","article-title":"Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge","volume":"24","author":"Pal","year":"2006","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.vaccine.2017.02.020","article-title":"The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge","volume":"35","author":"Pal","year":"2017","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pal, S., Slepenkin, A., Felgner, J., Huw Davies, D., Felgner, P., and de la Maza, L.M. (2023). Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with Chlamydia muridarum. Pathogens, 12.","DOI":"10.3390\/pathogens12070863"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.micinf.2013.11.009","article-title":"A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge","volume":"16","author":"Cheng","year":"2014","journal-title":"Microbes. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102257","DOI":"10.1016\/j.nano.2020.102257","article-title":"A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4(+) effector (CD44(high) CD62L(low)) and memory (CD44(high) CD62L(high)) T-cells in immunized mice","volume":"29","author":"Sahu","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.vaccine.2009.05.008","article-title":"Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1016\/j.vaccine.2010.09.040","article-title":"Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization","volume":"28","author":"Tifrea","year":"2010","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","article-title":"Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: A first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","volume":"19","author":"Abraham","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lorenzen, E., Contreras, V., Olsen, A.W., Andersen, P., Desjardins, D., Rosenkrands, I., Juel, H.B., Delache, B., Langlois, S., and Delaugerre, C. (2022). Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1057375"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41467-024-45526-2","article-title":"Immune signature of Chlamydia vaccine CTH522\/CAF(R)01 translates from mouse-to-human and induces durable protection in mice","volume":"15","author":"Olsen","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pollock, K.M., Borges, A.H., Cheeseman, H.M., Rosenkrands, I., Schmidt, K.L., Sondergaard, R.E., Day, S., Evans, A., McFarlane, L.R., and Joypooranachandran, J. (2024). An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): A phase 1, double-blind trial. Lancet Infect. Dis.","DOI":"10.1016\/S1473-3099(24)00147-6"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Madico, G., Gursky, O., Fairman, J., and Massari, P. (2017). Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens. Vaccines, 6.","DOI":"10.3390\/vaccines6010002"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41541-020-0182-9","article-title":"Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold","volume":"5","author":"Tifrea","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1110\/ps.051616206","article-title":"Identification of surface-exposed components of MOMP of Chlamydia trachomatis serovar F","volume":"15","author":"Wang","year":"2006","journal-title":"Protein Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jsb.2013.12.006","article-title":"Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition","volume":"185","author":"Kattner","year":"2014","journal-title":"J. Struct. Biol."},{"key":"ref_48","unstructured":"Schr\u00f6dinger, Inc. (2015). The PyMOL Molecular Graphics System, Version 1.8, Schr\u00f6dinger, Inc."},{"key":"ref_49","first-page":"681","article-title":"SOPMA: Significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments","volume":"11","author":"Geourjon","year":"1995","journal-title":"Comput. Appl. Biosci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ponomarenko, J., Bui, H.H., Li, W., Fusseder, N., Bourne, P.E., Sette, A., and Peters, B. (2008). ElliPro: A new structure-based tool for the prediction of antibody epitopes. BMC Bioinform., 9.","DOI":"10.1186\/1471-2105-9-514"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/pro.3501","article-title":"Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation","volume":"27","author":"Hepler","year":"2018","journal-title":"Protein Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.vaccine.2011.02.057","article-title":"Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model","volume":"29","author":"Cheng","year":"2011","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1128\/iai.56.4.885-891.1988","article-title":"Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity","volume":"56","author":"Peterson","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.vaccine.2007.11.080","article-title":"The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant","volume":"26","author":"Liu","year":"2008","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100805","DOI":"10.1016\/j.patter.2023.100805","article-title":"B-factor prediction in proteins using a sequence-based deep learning model","volume":"4","author":"Pandey","year":"2023","journal-title":"Patterns"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1021\/acs.chemrev.8b00290","article-title":"Utility of B-Factors in Protein Science: Interpreting Rigidity, Flexibility, and Internal Motion and Engineering Thermostability","volume":"119","author":"Sun","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pep.2005.04.021","article-title":"Improved purification of native meningococcal porin PorB and studies on its structure\/function","volume":"44","author":"Massari","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/cei.12841","article-title":"The genetic background influences the cellular and humoral immune responses to vaccines","volume":"186","author":"Zeng","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.007","article-title":"Immunomodulatory properties of the vaccine adjuvant alum","volume":"28","author":"Oleszycka","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Collar, A.L., Linville, A.C., Core, S.B., and Frietze, K.M. (2022). Epitope-Based Vaccines against the Chlamydia trachomatis Major Outer Membrane Protein Variable Domain 4 Elicit Protection in Mice. Vaccines, 10.","DOI":"10.3390\/vaccines10060875"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1073\/pnas.85.11.4000","article-title":"Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes","volume":"85","author":"Baehr","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1021\/acs.chemrev.7b00305","article-title":"Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation","volume":"118","author":"Zhou","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1080\/21645515.2016.1168958","article-title":"Phosphate substitution in an AlOOH-TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis","volume":"12","author":"Visan","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.molimm.2018.11.020","article-title":"Identification of B cell epitopes enhanced by protein unfolding and aggregation","volume":"105","author":"Eyes","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Athearn, K., Sample, C.J., Barefoot, B.E., Williams, K.L., and Ramsburg, E.A. (2012). Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1beta. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046516"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","article-title":"Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans","volume":"37","author":"Burny","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:18:44Z","timestamp":1760109524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/7\/789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":70,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["vaccines12070789"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12070789","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}